These findings highlight the potential of MAGI2 as a sensitive biomarker for podocyte injury and its diagnostic utility as a molecular discriminator in differentiating between primary FSGS and MCD in kidney biopsies. Here, MAGI2 is linked to focal segmental glomerulosclerosis.